【IPO追踪】自主开发减肥药，派格生物今起招股

Group 1 - The company, Paige Biotech (02565.HK), has launched an IPO, planning to issue 19,283,500 shares globally, with 17,355,000 shares for international offering and 1,928,500 shares for public offering in Hong Kong [1] - The offering price is set at HKD 15.60 per share, with estimated net proceeds of approximately HKD 231.8 million after deducting underwriting fees and estimated expenses [1] - The funds raised will be allocated as follows: approximately 50.2% for commercialization and indication expansion of the core product PB-119, and about 34.5% for further development of the main product PB-718 [1] Group 2 - Paege Biotech focuses on innovative therapies for chronic diseases, particularly in the metabolic disorder field, with a pipeline that includes one core product and five other candidates targeting common metabolic diseases [2] - The core product, PB-119, is a long-acting GLP-1 receptor agonist nearing commercialization, primarily for treating Type 2 Diabetes Mellitus (T2DM) and obesity, showing benefits in blood sugar control and cardiovascular health [2] - PB-119's new drug application for T2DM treatment was accepted by the National Medical Products Administration in September 2023, with expectations for approval in the first half of 2025 [2] Group 3 - The company faces intense competition in the T2DM and obesity markets from existing and candidate products, including various GLP-1-based therapies available in China and the U.S. [3] - The company has not yet commercialized any products, resulting in continuous losses, with a reported loss of CNY 279 million in 2023 and an expected loss of CNY 283 million in 2024 [3] - Other net income for the company was CNY 14.635 million in 2023, projected to decrease to CNY 7.007 million in 2024 [3]